Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD

Equities

300534

CNE100002CP5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
8.2 CNY 0.00% Intraday chart for Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD -0.85% -16.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Longshenrongfa Pharmaceutical Appoints Vice Chairman, Deputy General Manager MT
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Proposes Final Cash Dividend for 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD cancelled the transaction announced on July 17, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Longshenrongfa Pharmaceutical Renews Food Production License MT
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD announced that it expects to receive CNY 485.796067 million in funding from Gansu Pharmaceutical Investment Group Co., Ltd., Gansu Great Wall Xinglong Silk Road Fund Management Co., Ltd. and other investors. CI
An unknown buyer agreed to acquire 7.1% stake in Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD for CNY 234.5 million. CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chinese Shares Rebound; Longshenrongfa Pharma Rises 3.9% on Renewal of Drug Production License MT
Gansu Longshenrongfa Pharma Renews Drug Production License MT
Drug Regulator Approves Changes to Longshenrongfa Pharma's Drug Production License MT
Longshenrongfa Pharma Gets Nod for Proposed Changes in License MT
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd completed the acquisition of 70% stake in Gansu Pu'an Pharmaceutical Co.,Ltd. from Gansu Province Farms Agribusiness Ref co Group Ltd. CI
Longshenrongfa Pharma Gets Provincial Regulator's Nod for Cough Capsules MT
Gansu Longshenrongfa Leases Properties to Affiliates MT
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction MT
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD
More charts
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is a company mainly engaged in research and development, production and sales of Chinese traditional medicine. The Company operates two segments. The Pharmaceutical Manufacturing segments is involved in the production and sale of Chinese traditional medicine, health food and raw materials. Its primary product is Yuanhuzhitong dripping pills, which is used for the treatment of stomach pain, rib pain and headache. The Company also produces other drugs, including compound salvia miltiorrhiza tablets, anti-inflammatory and gallbladder tablets, as well as Sanqi injury tablets. The Sales and Logistics segment operates logistics and distribution business.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW